Tesofensine

Tesofensine (NS2330) is a triple monoamine reuptake inhibitor originally synthesized by NeuroSearch A/S and investigated for the treatment of neurodegenerative disorders. The compound inhibits presynaptic reuptake of serotonin, dopamine, and noradrenaline by blocking their respective transporters (SERT, DAT, NET), thereby increasing monoaminergic tone at synaptic clefts. This mechanism distinguishes tesofensine from sibutramine, which primarily affects serotonin and noradrenaline, and places it in a unique pharmacological class among appetite-modulating research compounds. The compound's structural features include a bicyclic tropane scaffold that confers selectivity for monoamine transporters relative to other receptor systems. Initial clinical development focused on Alzheimer's disease and Parkinson's disease, where monoaminergic deficits are well-documented in postmortem and neuroimaging studies. Phase II trials in Parkinson's disease did not demonstrate the expected efficacy for motor symptoms, though participants receiving tesofensine exhibited incidental and significant reductions in body weight that were not observed in placebo groups. This unexpected finding redirected research interest toward metabolic applications, particularly in the study of central nervous system regulation of energy balance. Research suggests that tesofensine's influence on weight may be a primary pharmacological effect rather than an incidental finding. Subsequent Phase II clinical studies focused explicitly on obesity demonstrated substantial reductions in body weight over a 24-week period. In a randomized, double-blind, placebo-controlled trial conducted in Denmark, participants receiving 0.5 mg/day lost an average of approximately 12.8 kg compared to approximately 2.2 kg in the placebo group, representing a clinically meaningful difference in body weight. Researchers observed that tesofensine appeared to reduce appetite and alter food preference toward lower-calorie options, suggesting effects on both appetite intensity and hedonic aspects of feeding. These data place tesofensine among the most weight-reducing pharmacological agents examined in controlled research settings at that dose level. Mechanistic studies in rodent models have helped clarify tesofensine's anorectic effects at the circuit level. Research indicates that the compound reduces food intake primarily through dopaminergic and noradrenergic pathways affecting hypothalamic circuits that regulate energy balance, with particular involvement of the arcuate nucleus and lateral hypothalamic area. Studies in diet-induced obese mice showed sustained reductions in caloric intake and body fat percentage over extended treatment periods without equivalent reductions in locomotor activity. Preclinical data also suggest that tesofensine increases energy expenditure to a modest degree, supporting a dual mechanism of weight reduction involving both reduced intake and altered metabolic rate. Tesofensine has been studied in combination paradigms to assess potential cardiovascular considerations associated with monoamine reuptake inhibition. Preclinical data suggest potential synergistic metabolic effects when paired with selective beta-1 adrenergic blockade (such as metoprolol), an approach explored to attenuate heart rate elevations observed in some study cohorts. Research suggests that careful dosing and combination strategies may modulate the pharmacodynamic profile in ways relevant to metabolic research design. These pharmacological interaction studies provide a framework for researchers investigating combined noradrenergic and adrenergic modulation in energy homeostasis models. References: [1] Astrup A, et al. (2008). Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 372(9653):1906-13. PMID: 19026583 [2] Lehr T, et al. (2008). Population pharmacokinetic modelling of tesofensine and its active metabolite M1 in obese patients. British Journal of Clinical Pharmacology. 67(1):29-41. PMID: 19133054 [3] Axel AM, et al. (2010). The effect of tesofensine on appetite sensations. Obesity. 18(4):730-8. PMID: 19816413 [4] Larsen PJ, et al. (2012). Monoaminergic involvement in the regulation of body weight. European Journal of Pharmacology. 681(1-3):32-40. PMID: 22230014 For research use only. Not for human or veterinary use.